Loading data for BOLT — first visit, this takes a few seconds.
Bolt Biotherapeutics Inc. (BOLT)
NasdaqCM: BOLT
· Real-Time Price · USD
3.20
-0.15 (-4.48%)
At close: Aug 17, 2026, 8:00 PM
Bolt Biotherapeutics Inc. (BOLT) Stock Price, Analysis & Data
-4.48% (1D)
No data available
| Bid | 2.42 |
| Market Cap | 6.16M |
| Revenue (ttm) | 4.7M |
| Net Income (ttm) | -28.74M |
| Beta | 1.08 |
| EPS (ttm) | -15.77 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.16 |
| P/B (ttm) | 0.49 |
| P/S (ttm) | 1.31 |
| Earnings Date | Aug 14, 2025 |
| Ask | 4.19 |
| Volume | 24,535 |
| Avg. Volume (20D) | 26,093 |
| Open | 3.23 |
| Previous Close | 3.35 |
| Day's Range | 3.20 - 3.74 |
| 52-Week Range | 3.13 - 7.20 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 23
Stock Exchange NasdaqCM
Ticker Symbol BOLT
Website https://www.boltbio.com
Financial Performance
In 2025, Bolt Biotherapeutics's revenue was 7.7M, an increase of 0.07% compared to the previous year's 7.69M. Earnings were -33.38M, a decrease of -47.12%.
Financial StatementsEarnings Surprise
Bolt Biotherapeutics has released their quarterly earnings on Aug 11, 2026:
Bolt Biotherapeutics Inc. is scheduled to release its earnings on Aug 14, 2025, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2